© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to July
selective oral serine protease FXia inhibitor
projected BID dosing in patients
from 1.8k cmpd protease inh. screen + SBDD
J. Med. Chem., Jun. 17, 2020
Novartis (NIBR), Basel, Switzerland
“compound 23” is an oral, selective Factor XIa inhibitor intended as an anticoagulation agent. Since the clinical translatability of FXIa inhibition in preclinical models hasn’t been established, this program was…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.